We use cookies to enhance your browsing experience and analyze site traffic. By continuing to use this site, you agree to our cookie policy. Privacy Policy

CompanyMarch 2, 2026

Clickmab Completes Seed+ Funding Round Led by Hualan Shares

Led by Hualan Shares with follow-on investment from XtalPi and Xichuangtou, this round will accelerate Click.mAb. platform iteration and proprietary data flywheel building.


Clickmab has completed its Seed+ funding round, led by Hualan Shares (301093.SZ), with follow-on participation from existing shareholders XtalPi (2228.HK) and Xichuangtou. Beyond strengthening the company's capital base, the round expands collaboration with industrial shareholders. Hualan Shares' industrial resources and XtalPi's algorithmic capabilities together create an end-to-end support system from frontier technology evolution to industrial implementation.

The new capital will be primarily used to expand high-quality proprietary training data and further improve Clickmab's epitope-specific AI de novo antibody design capability. Clickmab will continue strengthening its technical system and talent base, with the goal of making AI antibody design a more deterministic R&D paradigm.

"During this critical window for digital transformation in biopharma, Hualan Shares continues to back pioneers with deep technical foundations. Clickmab's work in generative AI antibodies strongly aligns with our vision. As lead investor, we will support Clickmab with industrial customer resources and supply-chain advantages, helping translate its AI capabilities into real clinical value."

Yimin Hua/Chairman, Hualan Shares

"We are grateful for the trust and long-term support from Hualan Shares, XtalPi, Xichuangtou, and our existing shareholders. Since 2021, we have focused on epitope-specific AI de novo antibody design and a closed-loop path combining data, models, and wet lab validation. We will continue investing in proprietary data and iteration to push the limits of Click.mAb. and make AI-driven de novo design a stronger engine for antibody discovery."

Dr. Tianyuan Wang/CEO, Clickmab

Shape the Future of Antibody Therapeutics Together

Clickmab is dedicated to empowering antibody discovery through generative AI and welcomes partners across the ecosystem.